protein kinase inhibitors	are	drugs
protein kinase inhibitors	treat	cancer
protein kinase inhibitors	target	tyrosine kinases
protein kinase inhibitors	inhibit	cell proliferation
protein kinase inhibitors	reduce	tumor growth
protein kinase inhibitors	cause	apoptosis
protein kinase inhibitors	induce	cell cycle arrest
protein kinase inhibitors	are	targeted therapy
protein kinase inhibitors	are	oral agents
protein kinase inhibitors	are	intravenous agents
protein kinase inhibitors	have	adverse events
adverse events	include	rash
adverse events	include	diarrhea
adverse events	include	hypertension
adverse events	include	cardiotoxicity
protein kinase inhibitors	require	dose adjustment
dose adjustment	based on	renal function
dose adjustment	based on	hepatic function
protein kinase inhibitors	are	metabolized by CYP3A4
CYP3A4	is	enzyme
protein kinase inhibitors	interact with	CYP3A4 inhibitors
CYP3A4 inhibitors	increase	drug exposure
protein kinase inhibitors	interact with	CYP3A4 inducers
CYP3A4 inducers	decrease	drug exposure
protein kinase inhibitors	are	contraindicated in	pregnancy
protein kinase inhibitors	are	contraindicated in	lactation
protein kinase inhibitors	are	contraindicated in	severe hepatic impairment
protein kinase inhibitors	are	contraindicated in	severe renal impairment
protein kinase inhibitors	are	contraindicated in	QT prolongation
protein kinase inhibitors	are	contraindicated in	hypersensitivity
protein kinase inhibitors	are	used in	metastatic disease
protein kinase inhibitors	are	used in	adjuvant therapy
protein kinase inhibitors	are	used in	neoadjuvant therapy
protein kinase inhibitors	are	used in	maintenance therapy
protein kinase inhibitors	are	used in	first-line therapy
protein kinase inhibitors	are	used in	second-line therapy
protein kinase inhibitors	are	used in	third-line therapy
protein kinase inhibitors	are	used in	refractory disease
protein kinase inhibitors	are	used in	combination therapy
combination therapy	includes	chemotherapy
combination therapy	includes	immunotherapy
combination therapy	includes	radiation
protein kinase inhibitors	are	associated with	resistance
resistance	develops via	secondary mutations
resistance	develops via	bypass signaling
resistance	develops via	drug efflux
protein kinase inhibitors	are	monitored by	pharmacokinetics
pharmacokinetics	measured by	plasma concentration
pharmacokinetics	measured by	AUC
pharmacokinetics	measured by	Cmax
protein kinase inhibitors	are	monitored by	biomarkers
biomarkers	include	EGFR mutation
biomarkers	include	BRAF mutation
biomarkers	include	ALK rearrangement
biomarkers	include	HER2 amplification
protein kinase inhibitors	are	associated with	survival benefit
survival benefit	measured by	overall survival
survival benefit	measured by	progression-free survival
protein kinase inhibitors	are	associated with	quality of life
quality of life	measured by	patient-reported outcomes
protein kinase inhibitors	are	associated with	cost
cost	includes	drug acquisition
cost	includes	monitoring
cost	includes	adverse event management
protein kinase inhibitors	are	included in	clinical guidelines
clinical guidelines	recommend	first-line therapy
clinical guidelines	recommend	second-line therapy
clinical guidelines	recommend	third-line therapy
clinical guidelines	recommend	combination therapy
clinical guidelines	recommend	dose adjustment
clinical guidelines	recommend	monitoring
clinical guidelines	recommend	biomarker testing
protein kinase inhibitors	are	studied in	clinical trials
clinical trials	evaluate	efficacy
clinical trials	evaluate	safety
clinical trials	evaluate	pharmacodynamics
clinical trials	evaluate	pharmacokinetics
protein kinase inhibitors	are	approved by	FDA
protein kinase inhibitors	are	approved by	EMA
protein kinase inhibitors	are	approved for	specific indications
specific indications	include	non-small cell lung cancer
specific indications	include	colorectal cancer
specific indications	include	breast cancer
specific indications	include	melanoma
specific indications	include	renal cell carcinoma
protein kinase inhibitors	are	contraindicated with	concurrent radiation
protein kinase inhibitors	are	contraindicated with	concurrent chemotherapy
protein kinase inhibitors	are	contraindicated with	concurrent immunotherapy
protein kinase inhibitors	are	contraindicated with	concurrent anticoagulation
protein kinase inhibitors	are	contraindicated with	concurrent antiplatelet
protein kinase inhibitors	are	contraindicated with	concurrent NSAIDs
protein kinase inhibitors	are	contraindicated with	concurrent steroids
protein kinase inhibitors	are	contraindicated with	concurrent biologics
protein kinase inhibitors	are	contraindicated with	concurrent biologic agents
protein kinase inhibitors	are	contraindicated with	concurrent monoclonal antibodies
protein kinase inhibitors	are	contraindicated with	concurrent small molecules
protein kinase inhibitors	are	contraindicated with	concurrent targeted therapy
protein kinase inhibitors	are	contraindicated with	concurrent endocrine therapy
protein kinase inhibitors	are	contraindicated with	concurrent hormone therapy
protein kinase inhibitors	are	contraindicated with	concurrent immunosuppressants
